Particle Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Particle Health provides a health data exchange API enabling healthcare apps to access longitudinal patient records from national networks with a single integration.
About
Particle Health is a health data exchange company founded in 2018 that provides developers and healthcare companies with a single API to access patient clinical records from national health information networks including CommonWell, Carequality, and others. The company abstracts the complexity of connecting to dozens of regional health information exchanges and national networks behind a simple developer-friendly API, enabling healthcare applications to retrieve longitudinal patient records including medical history, lab results, diagnoses, and medications from any participating provider. Particle raised $60M and serves digital health companies, telehealth platforms, health plans, and healthcare analytics firms that need access to real-world patient data to power clinical decision support, care management, and value-based care programs. The company provides HIPAA-compliant data access with identity verification and purpose-of-treatment validation to ensure appropriate use of patient records. Particle's API approach reduces the time and cost for healthcare companies to build clinical data infrastructure from months of complex integrations to days of API implementation.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.